We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and safety of transcatheter arterial chemoembolization combined with either <sup>125</sup>I seed implantation or apatinib in hepatocellular carcinoma with portal vein tumor thrombosis: A retrospective comparative study.
- Authors
Li, Yuanyuan; Li, Hailiang; Hu, Hongtao; Yuan, Hang; Zhao, Yan
- Abstract
<bold>Aims: </bold>The aims of the study were to compare the efficacy and safety between transcatheter arterial chemoembolization (TACE) combined with 125I seed implantation (TACE-125I) or with apatinib (TACE-Apatinib) in HCC-portal vein tumor thrombosis (PVTT) patients.<bold>Setting and Design: </bold>We retrospectively evaluated the medical records of consecutive patients with HCC-PVTT who had undergone treatment with either TACE-125I or TACE-Apatinib between January 2018 and June 2019.<bold>Materials and Methods: </bold>The response was assessed at the last follow-up, and the outcomes were compared between the two groups. Progression-free survival (PFS), overall survival (OS), and treatment-related complications were evaluated. Statistical analysis used the 2-sample Student's t-test and Fisher's exact test.<bold>Results: </bold>This study enrolled 48 patients; 21 were treated with TACE-Apatinib and 27 with TACE-125I. For PVTT, the disease control rate (DCR) was 23.81% in the TACE-Apatinib group and 77.78% in the TACE-125I group. The objective response rate (ORR) in the TACE-Apatinib group was remarkably lower. The DCR of intrahepatic lesions was 85.71% in the TACE-Apatinib group and 81.48% in the TACE-125I group. There was no statistically significant difference in the ORR of intrahepatic lesions. Median OS was significantly longer in the TACE-125I group (13.3 vs. 10.8 months). Similarly, the median PFS was significantly longer in the TACE-125I group (9.7. vs. 6.6 months). Multivariate and univariate analyses showed that TACE-125I was an independent prognostic factor for OS.<bold>Conclusions: </bold>Compared with TACE-Apatinib, TACE-125I seed implantation can effectively prolong PVTT progression, PFS, and OS in HCC patients with PVTT.
- Subjects
CHEMOEMBOLIZATION; DRUG efficacy; PORTAL vein; HEPATOCELLULAR carcinoma; PROGNOSIS; THROMBOSIS; ELEMENTAL diet; PYRIDINE; DISEASE progression; RESEARCH; LIVER tumors; CANCER invasiveness; TIME; RESEARCH methodology; ANTINEOPLASTIC agents; RETROSPECTIVE studies; MEDICAL cooperation; EVALUATION research; IODINE radioisotopes; COMPARATIVE studies; RADIOISOTOPE brachytherapy; COMBINED modality therapy; LONGITUDINAL method
- Publication
Journal of Cancer Research & Therapeutics, 2020, Vol 16, Issue 7, p1691
- ISSN
0973-1482
- Publication type
journal article
- DOI
10.4103/jcrt.JCRT_1587_20